



# Pharmaceuticals market access pathway in France

4<sup>th</sup> PPRI Conference, Vienna  
24 Octobre 2019




- ANSM: French Health Products Safety Agency
- EMA: European Medicines Agency
- MA: Marketing Authorisation
- HAS: French National Authority for Health
- CT: Transparency Commission

- SMR: Medical value
- ASMR: Added medical value
- CEESP: Economic assessment and public health Commission
- UNCAM: Sickness funds union
- CEPS: Healthcare products Pricing Committee



- ANSM: French Health Products Safety Agency
- EMA: European Medicines Agency
- MA: Marketing Authorisation
- HAS: French National Authority for Health
- CT: Transparency Commission

- SMR: Medical value
- ASMR: Added medical value
- CEESP: Economic assessment and public health Commission
- UNCAM: Sickness funds union
- CEPS: Healthcare products Pricing Committee




## EARLY ACCESS SCHEMES

Scheme name	Regulatory status
Temporary use authorisation (ATU) Temporary use recommandation (RTU)	Coverage before a Marketing authorisation (MA)
ATU for new indication (post-ATU direct) ATU for new indication (ATU EIT)	Coverage after a MA


- ANSM: French Health Products Safety Agency
- EMA: European Medicines Agency
- MA: Marketing Authorisation
- HAS: French National Authority for Health
- CT: Transparency Commission

- SMR: Medical value
- ASMR: Added medical value
- CEESP: Economic assessment and public health Commission
- UNCAM: Sickness funds union
- CEPS: Healthcare products Pricing Committee




- ANSM: French Health Products Safety Agency
- EMA: European Medicines Agency
- MA: Marketing Authorisation
- HAS: French National Authority for Health
- CT: Transparency Commission

- SMR: Medical value
- ASMR: Added medical value
- CEESP: Economic assessment and public health Commission
- UNCAM: Sickness funds union
- CEPS: Healthcare products Pricing Committee



- ANSM: French Health Products Safety Agency
- EMA: European Medicines Agency
- MA: Marketing Authorisation
- HAS: French National Authority for Health
- CT: Transparency Commission

- SMR: Medical value
- ASMR: Added medical value
- CEESP: Economic assessment and public health Commission
- UNCAM: Sickness funds union
- CEPS: Healthcare products Pricing Committee



## Reimbursement criteria


Reimbursement rates are driven by SMR

SMR important	}	65 %
SMR moderate		35 %
SMR weak		15 %
SMR insufficient		0%

Drugs treating severe and chronic disease (ALD) and in-patient drugs are covered 100 %

- ANSM: French Health Products Safety Agency
- EMA: European Medicines Agency
- MA: Marketing Authorisation
- HAS: French National Authority for Health
- CT: Transparency Commission

- SMR: Medical value
- ASMR: Added medical value
- CEESP: Economic assessment and public health Commission
- UNCAM: Sickness funds union
- CEPS: Healthcare products Pricing Committee



## Pricing Criteria


set by law (Art. L162-16-4 Social Security Code)

- Added medical value (ASMR)
- Economic assessment
- Comparators prices
- Sales forecast
- Use conditions

- ANSM: French Health Products Safety Agency
- EMA: European Medicines Agency
- MA: Marketing Authorisation
- HAS: French National Authority for Health
- CT: Transparency Commission

- SMR: Medical value
- ASMR: Added medical value
- CEEESP: Economic assessment and public health Commission
- UNCAM: Sickness funds union
- CEPS: Healthcare products Pricing Committee





## Pricing criteria

*Pricing decisions are mostly driven by ASMR*

ASMR I	major added value	}	price > comparators
ASMR II	important added value		price > comparators
ASMR III	significant added value		price > comparators
ASMR IV	minor added value		price = comparators
ASMR V	no added value		price < comparators

- ANSM: French Health Products Safety Agency
- EMA: European Medicines Agency
- MA: Marketing Authorisation
- HAS: French National Authority for Health
- CT: Transparency Commission

- SMR: Medical value
- ASMR: Added medical value
- CEESP: Economic assessment and public health Commission
- UNCAM: Sickness funds union
- CEPS: Healthcare products Pricing Committee

# Thank you

Jonathan Rodrigues  
jonathan.rodrigues@sante.gouv.fr